AtriCure
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
AtriCure, Inc. creates, produces, and markets medical devices for the surgical treatment of cardiac tissue and intercostal nerves. Its market reach spans the United States, Europe, Asia, and other int...
Latest News
8 days ago · seekingalpha.com
AtriCure, Inc. (ATRC) Presents at 2026 UBS Global Healthcare Conference TranscriptAtriCure, Inc. ( ATRC ) 2026 UBS Global Healthcare Conference November 9, 2026 11:00 AM EST Company Participants Angela Wirick - Chief Financial Officer Conference Call Participants Patrick Andrew Wood - UBS Investment Bank, Research Division Presentation Patrick Andrew Wood UBS Investment Bank, Research Division Welcome. Thanks, everyone.
9 days ago · seekingalpha.com
AtriCure: A New Quality Metric Could Put A Clip In Nearly Every SternotomyAtriCure is shifting from targeting AF patients to all open-heart surgery patients, aiming for broader adoption as a preventive standard of care. Upcoming catalysts include the STS quality metric rollout in 2027, BoxX-NoAF trial results in spring 2027, and the LeAAPS trial, all supporting institutional adoption. ATRC achieved GAAP profitability, with Q3 revenue up 15% year-over-year and adjusted EBITDA up 50.6%, signaling strong operating leverage and healthy cash generation.
13 days ago · benzinga.com
AtriCure Analysts Boost Their Forecasts After Better-Than-Expected Q3 ResultsAtriCure, Inc. (NASDAQ:ATRC) on Tuesday posted upbeat results for the third quarter.
13 days ago · seekingalpha.com
AtriCure, Inc. (ATRC) Q3 2026 Earnings Call TranscriptAtriCure, Inc. ( ATRC ) Q3 2026 Earnings Call November 3, 2026 4:30 PM EST Company Participants Michael H. Carrel - CEO, President & Director Angela Wirick - Chief Financial Officer Conference Call Participants Marissa Bych - Gilmartin Group LLC Matthew O'Brien - Piper Sandler & Co., Research Division John Young - Canaccord Genuity Corp., Research Division Marie Thibault - BTIG, LLC, Research Division Lilia-Celine Lozada - JPMorgan Chase & Co, Research Division Joseph Conway - Needham & Company, LLC, Research Division Daniel Stauder - Citizens JMP Securities, LLC, Research Division Keith Hinton - Prime Executions, Inc., Research Division Suraj Kalia - Oppenheimer & Co. Inc., Research Division Presentation Operator Good afternoon, and welcome to AtriCure's Third Quarter 2026 Earnings Conference Call.
13 days ago · marketbeat.com
What AtriCure (ATRC) Said on Its Q3 Earnings CallAtriCure NASDAQ: ATRC reported third-quarter 2026 revenue of $154.5 million, up 15% from a year earlier, as growth in its U.S. open ablation, appendage management and pain management businesses helped lift profitability.
13 days ago · zacks.com
Compared to Estimates, AtriCure (ATRC) Q3 Earnings: A Look at Key MetricsThe headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
13 days ago · zacks.com
AtriCure (ATRC) Beats Q3 Earnings and Revenue EstimatesAtriCure (ATRC) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to a loss of $0.01 per share a year ago.
1 month ago · businesswire.com
AtriCure to Announce Third Quarter 2026 Financial ResultsMASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its third quarter 2026 financial results on Tuesday, November 3, 2026. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, November 3, 2026, to discuss its third quarter financial results. Those interested in liste.
2 months ago · zacks.com
Is AtriCure (ATRC) Stock Outpacing Its Medical Peers This Year?Here is how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
2 months ago · zacks.com
Do Options Traders Know Something About AtriCure Stock We Don't?Investors need to pay close attention to ATRC stock based on the movements in the options market lately.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove ATRC